阿利西尤单抗对冠心病介入治疗患者冠脉微循环及VEGF超家族指标的影响OA

Objective:To investigate the influence of Alirocumab for coronary microcirculation and vascular endothelial growth factor(VEGF)superfamily indicators of patients with intervention for coronary heart disease.Method:A total of 100 patients with intervention for coronary heart disease in Jiaozhou Hospital,Dongfang Hospital Affiliated to Tongji University from October 2022 to February 2024 were divided into the control group(n=50)and the observation group(n=50)according to the random number table method.The control group received conventional treatment,while the observation group was treated with Alirocumab in addition to the control group.Both groups were treated for 6 months.The incidence of adverse reactions,the incidence of major cardiovascular adverse events,the levels of blood lipid(TC,TG and LDL-C),coronary microcirculation[index of microcirculatory resistance(IMR)and coronary flow reserve(CFR)]and VEGF superfamily indicators(VEGF-A,VEGF-B and VEGF-C)before and after treatment were compared between the two groups.Result:There were no statistically significant differences in the incidences of various adverse reactions between the two groups(P>0.05).The incidence of major cardiovascular adverse events in the observation group was significantly lower than that in the control group(P<0.05).After 3 and 6 months of treatment,TC,TG,LDL-C,IMR,VEGF-A,VEGF-B and VEGF-C in the observation group were significantly lower than those in the control group,and CFR was significantly higher than that in the control group(P<0.05).Conclusion:Alirocumab can significantly control the blood lipid levels and major cardiovascular adverse events rates of patients with intervention for coronary heart disease,and it can effectively improve the coronary microcirculation and expression of VEGF superfamily of patients.